Literature DB >> 11976072

Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings in EUROASPIRE II.

Guy De Backer1.   

Abstract

Recommendations for reducing risk of recurrence in patients with established coronary heart disease (CHD) or other atherosclerotic disease were published by the Joint European Societies in 1994 and 1998. The first EUROASPIRE survey of clinical practice of secondary CHD prevention, performed in 1995 and 1996, found that 19% of CHD patients smoked cigarettes, 25% had body mass index (BMI) > or =30 kg/m(2), 53% had blood pressure > or =140/90 mmHg, and 44% had plasma total cholesterol > or =5.5 mmol/l. EUROASPIRE II, conducted in 1999 and 2000, found that 21% of patients smoked cigarettes, 31% had BMI > or =30 kg/m(2), 50% had blood pressure > or =140/90 mmHg, and 58% had serum total cholesterol > or =5.0 mmol/l. It is clear that there are still considerable opportunities in Europe to reduce risk of recurrent CHD through lifestyle changes, rigorous control of other risk factors, and more effective use of proven drug therapies.

Entities:  

Mesh:

Year:  2002        PMID: 11976072     DOI: 10.1016/s1567-5688(01)00017-4

Source DB:  PubMed          Journal:  Atheroscler Suppl        ISSN: 1567-5688            Impact factor:   3.235


  7 in total

1.  Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway.

Authors:  John R Cook; Don Yin; Evo Alemao; Glenn Davies; Karl J Krobot; Enrico Veltri; Leslie Lipka; Xavier Badia
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  2008 white paper for implementing strategies and interventions for cardiovascular prevention in Italy.

Authors:  Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-03

3.  Mortality after acute myocardial infarction according to income and education.

Authors:  Jeppe N Rasmussen; Søren Rasmussen; Gunnar H Gislason; Pernille Buch; Steen Z Abildstrom; Lars Køber; Merete Osler; Finn Diderichsen; Christian Torp-Pedersen; Mette Madsen
Journal:  J Epidemiol Community Health       Date:  2006-04       Impact factor: 3.710

Review 4.  Atorvastatin: pharmacological characteristics and lipid-lowering effects.

Authors:  Andrea Poli
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.

Authors:  Franz H Messerli; George L Bakris; David Ferrera; Mark C Houston; Robert J Petrella; John M Flack; William Sun; EunMee Lee; Joel M Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-08       Impact factor: 3.738

6.  A pharmacist-led follow-up program for patients with established coronary heart disease in North Norway - a randomized controlled trial.

Authors:  Beate H Garcia; Trude Giverhaug; June U Høgli; Frode Skjold; Lars Småbrekke
Journal:  Pharm Pract (Granada)       Date:  2015-06-15

7.  Assessing compliance of cardiologists with the national cholesterol education program (NCEP) III guidelines in an ambulatory care setting.

Authors:  Zakari Y Aliyu; Sohair B Yousif; Kate Plantholt; Hamisu M Salihu; Ayodele Erinle; Steve Plantholt
Journal:  Lipids Health Dis       Date:  2004-05-12       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.